Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.52 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706194 | 0.87 | TLR7 (0.67) | TLR7TLR8NUDT1 | |
| SCHEMBL5451703 | 0.85 | TLR7 (0.56) | TLR7TLR8NUDT1 | |
| SCHEMBL1890829 | 0.85 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL22158729 | 0.84 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL31355424 | 0.82 | TLR7 (0.78) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL22158717 | 0.82 | TLR7 (0.78) | TLR7TLR8NUDT1 | |
| SCHEMBL6719547 | 0.81 | TLR7 (0.51) | TLR7TLR8NUDT1 | |
| SCHEMBL1895853 | 0.81 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL6726559 | 0.81 | TLR7 (0.51) | TLR7TLR8NUDT1 | |
| SCHEMBL22158688 | 0.80 | TLR7 (0.47) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12077535-B2 | Derivatives of resiquimod | SUPERB WISDOM LIMITED (WS) | 2024-09-03 | — | — | US | disclosed |
| US-20230002370-A1 | DERIVATIVES OF RESIQUIMOD | SUPERB WISDOM LIMITED (WS) | 2023-01-05 | — | — | US | disclosed |
| US-11274099-B2 | Derivatives of Resiquimod | SUPERB WISDOM LIMITED (WS) | 2022-03-15 | — | — | US | disclosed |
| US-20200207757-A1 | DERIVATIVES OF RESIQUIMOD | SUPERB WISDOM LIMITED (WS) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207757-A1 | DERIVATIVES OF RESIQUIMOD | MYD88, TLR7, HLA-DRB1 | TLR7 2/4885TLR8 28/4885NUDT1 209/4885 |
| US-20230002370-A1 | DERIVATIVES OF RESIQUIMOD | MYD88, TLR7, HLA-DRB1 | TLR7 2/4885TLR8 28/4885NUDT1 209/4885 |
| US-11274099-B2 | Derivatives of Resiquimod | MYD88, TLR7, HLA-DRB1 | TLR7 2/4885TLR8 28/4885NUDT1 209/4885 |
| US-12077535-B2 | Derivatives of resiquimod | MYD88, TLR7, HLA-DRB1 | TLR7 2/4885TLR8 28/4885NUDT1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.